EXPERIENCE WITH DEFERASIROX FOR IRON OVERLOAD AFTER RED BLOOD CELL TRANSFUSION

スポンサーリンク

概要

• 論文の詳細を見る

• We analyzed the effect of deferasirox (DFX) therapy in 73 patients with a nonelective need for blood transfusion. Median age was 67 years (20-89). Median observation period was 182 days (19-428). Among 73 evaluable patients, 3 were able to discontinue DFX after achieving a predetermined treatment goal (SF<500), 19 had significant decrease in SF, and 17 failed to show significant response. Among 36 patients who were able to continue DFX for more than 6 months, serum ferritin (SF) levels were decreased by an average of 103ng/ml per month. In contrast, 17 patients (23.3%) discontinued DFX because of adverse effects, including digestive organ symptoms and renal function abnormalities. There were difficulties in sufficiently increasing the dose of DFX because of adverse effects. In order to fully perform chelation therapy with DFX, it is important to start administration of DFX from a low dose at an early stage of iron overload.

• 一般社団法人 日本輸血・細胞治療学会の論文

一般社団法人 日本輸血・細胞治療学会 | 論文

• A patient transfused with HBV-DNA-positive platelet concentrate negative on 50-pool nucleic acid amplification testing.
• THE PRESENT CONDITIONS AND PROBLEMS OF NURSES WORKING AT TRANSFUSION SECTIONS IN JAPANESE HOSPITALS: FOR THE ESTABLISHMENT OF A CERTIFIED TRANSFUSION NURSE:FOR THE ESTABLISHMENT OF A CERTIFIED TRANSFUSION NURSE
• Analysis of ABH antigens in erythrocytes after ABO-Incompatible bone marrow transplantation.
• SUCCESSFUL CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CASE OF ACUTE MYELOID LEUKEMIA WITH IgA DEFICIENCY
• STATISTICAL OBSERVATIONS ON POST TRANSFUSION JAUNDICE

もっと見る

スポンサーリンク